Table 3.

Immunotherapy for recurrent hepatocellular carcinoma after liver transplantation

Patient	Age	Ref.	Tumour	Agent	Years after LT	Immunosuppression	Prior sorafenib	Response	OS (mo)	Rejection
1	41	De Toni et al[63], 2017	HCC	Nivolumab	1	Low dose tacrolimus	Yes	No	-	No
21	20	Friend et al[64], 2017	HCC	Nivolumab	4	Sirolimus	-	-	1	Yes
31	14	Friend et al[64], 2017	HCC	Nivolumab	3	Tacrolimus	-	-	1	Yes
4	70	Varkaris et al[65], 2017	HCC	Pembrolizumab	8	Low dose tacrolimus	Yes	No	3	No
5	57	DeLeon et al[66], 2018	HCC	Nivolumab	2.7	Tacrolimus	Yes	No	1.2	No
6	56	DeLeon et al[66], 2018	HCC	Nivolumab	7.8	MMF/sirolimus	Yes	No	1.1	No
7	35	DeLeon et al[66], 2018	HCC	Nivolumab	3.7	Tacrolimus	Yes	No	1.3	No
8	64	DeLeon et al[66], 2018	HCC	Nivolumab	1.2	Tacrolimus	Yes	-2	0.3	No
9	68	DeLeon et al[66], 2018	HCC	Nivolumab	1.1	Sirolimus	Yes	-	0.7	Yes
10	70	Varkaris et al[65], 2017	HCC	Pembrolizumab	6	Low dose tacrolimus	Yes	No	3	No
11	59	Ranganath et al[69], 2015	Melanoma	Ipilimumab	8	Tacrolimus	-	-	-	No
12	67	Morales et al[70], 2015	Melanoma	Ipilimumab	8	Sirolimus	-	-	-	No
13	55	DeLeon et al[66], 2018	Melanoma	Pembrolizumab	5.5	MMF/everolimus	-	-	-	No
14	63	DeLeon et al[66], 2018	Melanoma	Pembrolizumab	3.1	MMF/prednisolone	-	-	-	Yes
15	62	Kuo et al[71], 2018	Melanoma	Ipilimumab and pembrolizumab	6	Sirolimus	-	-	-	Yes

¹Fibrolamella hepatocellular carcinoma;

²Multiorgan failure, unrelated to immunotherapy. HCC: Hepatocellular carcinoma; LT: Liver transplant; OS: Overall survival.